Product image of Letzo (Letrozole) supplied by GNH India

Letzo

Active Ingredient:
Letrozole
Origin:
EU

Letzo (Letrozole)

Letrozole, the active ingredient in Letzo, is an aromatase inhibitor presented as an oral formulation for oral use. It is used in the endocrine therapy of estrogen receptor‑positive breast cancer in postmenopausal women, helping to reduce estrogen production that can stimulate tumor growth. The drug works by reversibly binding to the aromatase enzyme, thereby decreasing the conversion of androgens to estrogens. Clinical studies have demonstrated its efficacy in both early‑stage and advanced disease settings, making it a cornerstone of hormonal management for this patient population.

GNH India supplies Letzo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Rowex Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is indicated for hormone‑dependent breast cancer and works within the estrogen signaling pathway.

  • Adjuvant treatment of early‑stage estrogen receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence after surgery.
  • Metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows tumor progression and extends survival.
  • Neoadjuvant therapy for estrogen receptor‑positive breast cancer in postmenopausal women: decreases tumor size before surgery.

How It Works

  • Letrozole exerts its effect by reversibly inhibiting the aromatase enzyme (CYP19A1), which is responsible for converting adrenal and ovarian androgens into estrone and estradiol. By blocking this conversion, systemic estrogen levels decline, depriving estrogen‑dependent tumor cells of a growth stimulus. The inhibition is dose‑dependent and persists for several days after the drug is cleared, providing sustained hormonal suppression.

Side Effects

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Joint and muscle pain: aches in joints or muscles.
  • Fatigue: persistent tiredness.
  • Nausea: mild to moderate upset stomach.
  • Headache: pressure or throbbing pain.
  • Weight gain: increase in body weight.

Serious or Rare Side Effects

  • Severe bone loss: increased risk of osteoporosis and fractures.
  • Cardiovascular events: blood clots or stroke.
  • Liver toxicity: elevated liver enzymes or hepatitis.
  • Allergic reactions: rash, itching, swelling, or anaphylaxis.

Precautions & Warnings

Before initiating Letzo, clinicians should consider several safety measures and monitoring requirements.

  • Assess bone health: baseline DEXA scan recommended.
  • Monitor liver function: periodic liver enzyme tests.
  • Evaluate cardiovascular risk: check blood pressure and lipid profile.
  • Avoid use in premenopausal women: drug is ineffective without ovarian suppression.
  • Inform patients about potential hot flashes and joint pain.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid)

  • Concurrent use with estrogen‑containing hormone therapy: negates aromatase inhibition.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels.
  • Tamoxifen: antagonistic effects on estrogen pathways.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may increase bleeding risk.
  • Selective serotonin reuptake inhibitors (SSRIs): possible additive effect on bone density loss.
  • Cholesterol‑lowering agents (statins): monitor liver function.

Frequently Asked Questions

Letzo contains letrozole, an aromatase inhibitor that is used in the endocrine treatment of estrogen receptor‑positive breast cancer in postmenopausal women. It is prescribed for adjuvant, neoadjuvant, and metastatic settings to lower estrogen levels and help control tumor growth.

Letrozole works by reversibly binding to the aromatase enzyme (CYP19A1), which converts androgens into estrogens. By inhibiting this enzyme, the drug reduces circulating estrogen concentrations, depriving estrogen‑dependent cancer cells of a key growth signal.

The dose of Letzo is determined by the prescribing clinician based on the patient’s clinical condition, disease stage, and response to therapy. Physicians typically follow established dosing guidelines, but the exact regimen is individualized and should not be altered without medical advice.

Letzo is contraindicated in pregnancy because it can harm a developing fetus by suppressing estrogen. Safety during breastfeeding has not been established, and the drug may pass into breast milk. Women of child‑bearing potential should use effective contraception while on therapy.

To order Letzo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letzo (letrozole) belongs to the aromatase inhibitor class, similar to anastrozole and exemestane. Compared with anastrozole, letrozole generally provides a slightly stronger suppression of estrogen levels, which may translate into marginally better disease control in some patients, though individual response varies.

Letzo should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Letzo is taken orally, usually as a single tablet taken once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with water and follow any specific instructions regarding timing relative to meals.

Serious risks associated with Letzo include severe bone loss leading to osteoporosis or fractures, cardiovascular events such as blood clots or stroke, and liver toxicity. Patients should report new bone pain, signs of liver dysfunction, or unexplained swelling promptly to their healthcare provider.

Letzo should not be used in premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any component of the formulation. Caution is also advised for patients with severe liver impairment or uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT